Adicet Bio, Inc

Adicet Bio, Inc (NASDAQ: ACET) is a clinical-stage biotechnology firm focused on developing a portfolio of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), designed to deliver sustained therapeutic responses in patients.

Key Business Updates

• Financial Performance Overview: For the quarter ended June 30, 2025 (Q2 FY2025), Adicet Bio recorded a net loss of USD 31.2 million, compared to USD 29.9 million in the prior-year quarter (Q2 FY2024), marking a 4% year-over-year increase. Total operating expenses were relatively flat at USD 32.4 million in Q2 FY2025, against USD 32.8 million in Q2 FY2024, indicating effective cost containment despite higher clinical activity. The loss per share stood at USD 0.34, marginally up from USD 0.33 in the previous year, primarily reflecting lower interest income and a higher share base.
• Research and Development Investment: Research and development (R&D) expenses rose 10% year-over-year, from USD 25.9 million in Q2 FY2024 to USD 28.4 million in Q2 FY2025. This increase was mainly due to higher external development costs linked to contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), as well as additional facility-related costs. However, the rise was partially offset by reduced payroll and lower stock-based compensation. The growth in R&D reflects the company’s continued progress in advancing ADI-001 for autoimmune indications and ADI-212, its PSMA-targeted oncology candidate.
• Administrative Efficiency and Cost Management: General and administrative (G&A) expenses decreased by 43% year-over-year, from USD 6.9 million in Q2 FY2024 to USD 4.0 million in Q2 FY2025. The decline was primarily driven by lower personnel costs and reduced stock-based compensation, alongside facility cost optimizations. This marked improvement highlights management’s focus on operational efficiency, ensuring that resources are prioritized toward core research programs amid ongoing market challenges.
• Non-Operating Income and Other Expenses: Interest income declined sharply by 53%, falling from USD 3.0 million in Q2 FY2024 to USD 1.4 million in Q2 FY2025, mainly due to lower cash balances and moderating yields on short-term investments. Additionally, other expenses rose from USD 0.05 million to USD 0.22 million, a 337% increase, largely resulting from higher franchise taxes and minor equipment losses. The combined impact of reduced interest income and increased miscellaneous costs marginally widened the net loss during the quarter.
• Liquidity and Balance Sheet Position: The company’s liquidity position weakened over the past year, with cash, cash equivalents, and short-term investments totaling USD 124.9 million as of June 30, 2025, compared to USD 224.1 million as of June 30, 2024 — a 44% decline. Total stockholders’ equity also fell by 29%, from USD 186.6 million at December 31, 2024, to USD 133.4 million at June 30, 2025. Adicet expects continued operating losses in the near term, driven by ongoing clinical development and manufacturing costs, and may require additional equity or debt financing to sustain operations beyond its current cash runway.
• Strategic Realignment: In July 2025, Adicet announced a 30% workforce reduction and a pipeline prioritization initiative, emphasizing ADI-001 and ADI-212 as core assets while discontinuing ADI-270. The realignment is expected to incur one-time restructuring costs of approximately USD 2.3 million in Q3 FY2025, aimed at extending the company’s cash runway and improving long-term R&D efficiency. This restructuring underscores management’s focus on maintaining strategic flexibility and optimizing capital deployment in a constrained funding environment.

Technical Observation (on the daily chart):

The short-term outlook for ACET remains constructive. As long as the stock maintains its position above the crucial support of the 20-day and 50-day moving averages, the bullish case for an early-stage trend reversal holds. A decisive and sustained break above the recent high of $1.00 would be the next major confirmation of a new uptrend. Conversely, a failure to hold support at the moving averages would signal a potential return to the prior bearish trend.

Adicet Bio, Inc. (NASDAQ: ACET) shows signs of a potential trend reversal, holding above its 20-day and 50-day moving averages. A breakout above $1.00 could confirm upside momentum, while a drop below key supports may revive bearish pressure. Rated ‘Speculative Buy’ to Adicet Bio, Inc (NASDAQ: ACET) at the closing market price of USD 0.85 as of Oct 07,2025.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is October 07,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.